Bionetix, ProQinase, and MercachemSyncom announce a joint research project from target Identification to clinical study
Korea, Germany, Netherlands, January 24, 2020
Completion of a stock swap transaction whereby RBC has acquired all the shares of ProQinase GmbH.
Malvern (USA) and Beijing (China), February 1, 2019
A new EU-funded industry-academia drug discovery partnership targets challenging kinases.
Freiburg, April 10, 2013
German research alliance BioTag to develop new biomarker screens to measure tumor response to innovative protein kinase inhibitors.
Reutlingen and Freiburg, September 14, 2009
Crelux and ProQinase establish joint crystal-grade kinse protein and structures platform.
Munich and Freiburg, May 7, 2008
ProQinase will identify novel biomarkers for anti-tumor therapies as member of the EU-research consortium "ANGIOTARGETING".
Freiburg, February 2007
ChemDiv, Inc. and ProQinase GmbH to Partner in Lead Discovery and Preclinical Development in Oncology.
San Diego and Freiburg, November 7, 2005
ProQinase and University of Duesseldorf receive BMBF-Grant for German-Chinese Research Project for the discovery of novel drugs for the treatment of cancer.
Duesseldorf and Freiburg, July 18, 2005
MorphoSys Antibodies by Design, ProQinase and Natural and Medical Sciences Institute (NMI) receive BMBF-promotion for Kinome-project.
Martinsried/Munich, Freiburg and Reutlingen, June 17, 2005
ProQinase participates in EU FP6 Research Program „Protein Kinases – Novel Drug Targets of Post Genomic Era".
Freiburg, October 2004
4SC and ProQinase collaborate on the discovery of new protein kinase inhibitors for cancer treatment.
Martinsried and Freiburg, Germany, April 28, 2003
ProQinase receives "Freiburg Innovation Award 2002" for its Integrated Technology Platform Protein Kinases.
Freiburg, Germany, January 23, 2003